Protara Therapeutics (TARA) Return on Capital Employed (2014 - 2026)

Protara Therapeutics' Return on Capital Employed history runs 13 years deep, the most recent figure standing at 36.53% for Q1 2026.

• In Q1 2026, Return on Capital Employed fell 592.0% year-over-year to 36.53%; the TTM figure through Mar 2026 stood at 36.53% (down 592.0% YoY), while the FY2025 annual figure was 34.98%, up 624.0% from the prior year.
• Return on Capital Employed was 36.53% for Q1 2026 at Protara Therapeutics, up from 38.86% in the prior quarter.
• In the past five years, Return on Capital Employed ranged from a high of 25.56% in Q3 2022 to a low of 84.77% in Q3 2023.
• Historically, Return on Capital Employed has averaged 47.59% across 5 years, with a median of 42.44% in 2025.
• The sharpest annual moves came in 2023 and 2025: Return on Capital Employed slumped 5921 bps in 2023, then jumped 3660 bps in 2025.
• A 5-year view of Return on Capital Employed shows it stood at 53.56% in 2022, then dropped by 5 bps to 56.23% in 2023, then surged by 31 bps to 38.76% in 2024, then retreated by 0 bps to 38.86% in 2025, then increased by 6 bps to 36.53% in 2026.
• The last three Return on Capital Employed figures came in at 36.53% (Q1 2026), 38.86% (Q4 2025), and 42.44% (Q3 2025), per Business Quant data.